Cover Image
市場調查報告書

腫瘤學生技仿製藥的全球市場:2016∼2020年

Global Oncology Biosimilars Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 319672
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
腫瘤學生技仿製藥的全球市場:2016∼2020年 Global Oncology Biosimilars Market 2016-2020
出版日期: 2016年02月17日 內容資訊: 英文 109 Pages
簡介

癌症由於治療費用高等成為醫療制度的龐大負擔。由於許多癌症治療藥的專利失效,生技仿製藥進入市場。生技仿製藥、由單株抗體、蛋白質、荷爾蒙、核酸、細胞聚落刺激因子、白細胞介素,酵素等生物學因素合成。全球腫瘤學生技仿製藥市場,預計2016∼2020年以年複合成長率31.76%擴大。

本報告提供全球腫瘤學生技仿製藥市場現狀與今後的成長預測,各地區趨勢,以及市場趨勢與課題,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 癌症概要

  • 流行病學
  • 癌症的經濟負擔

第6章 生技仿製藥產業

  • 生技仿製藥和非專利小分子的比較
  • 生技藥品和生技仿製藥的影響因素
  • 生技仿製藥:商務和價格策略
  • 生技仿製藥攝取的影響因素
  • 生技仿製藥的機器
  • 生技仿製藥的成長
  • 在各種地區的首發品和生技仿製藥的市場普及度
  • 全球腫瘤學生技仿製藥市場關於現在及未來趨勢
  • 新加入廠商者的相關課題

第7章 全球醫藥品市場

  • 市場規模預測
  • 全球生技仿製藥市場

第8章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第9章 各終端用戶市場區隔

  • 醫院
  • 零售藥局

第10章 各用途市場市場區隔

  • 癌症治療藥
  • 補充的照護藥物

第11章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 主要地區

  • 美國
  • 歐洲
  • 日本
  • 印度
  • 中國

第13章 推動市場的要素

第14章 促進要素的影響

第15章 市場課題

第16章 促進要素及課題的影響

第17章 市場趨勢

第18章 供應商環境

  • 競爭模式
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR8749

About Oncology Biosimilars

Cancer represents a huge burden on healthcare systems worldwide due to the high cost of treatment therapeutics. The patent expiry of many cancer therapeutics enables the entry of biosimilars into the market. Biosimilars are being incorporated into oncology treatment practices in the supportive care setting. Biosimilars are synthesized with the use of biologic components such as monoclonal antibodies, proteins, hormones, nucleic acids, colony stimulating factors, interleukins, and enzymes.

Technavio's analysts forecast the global oncology biosimilars market to grow at a CAGR of 31.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global oncology biosimilars market for the period 2016-2020. To calculate the market size, the report considers revenue generated from the sales of biosimilars used to treat cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Oncology Biosimilars Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F. Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz

Other Prominent Vendors

  • AbbVie
  • Allergan
  • Amgen
  • AstraZeneca
  • Baxter
  • Biogen
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Cipla
  • Coherus BioSciences
  • Coherus BioSciences
  • Daiichi Sankyo
  • Emcure Pharmaceuticals
  • GlaxoSmithKline (GSK)
  • Intas Pharmaceuticals
  • Merck
  • Pfizer
  • Sanofi
  • 3SBio
  • Wockhardt

Market driver

  • Rise in number of patent expiries
  • For a full, detailed list, view our report

Market challenge

  • Risks related to failure of drugs in the market
  • For a full, detailed list, view our report

Market trend

  • Emergence of biosimilars
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Overview of cancer

  • Epidemiology
  • Economic burden of cancer

PART 06: Biosimilars industry

  • Comparison between biosimilars and generic small molecules
  • Factors influencing biologics and biosimilars
  • Biosimilars: business and pricing strategy
  • Factors affecting the uptake of biosimilars
  • Biosimilar opportunities
  • Growth of biosimilars 2014- 2020
  • Market penetration of originators and biosimilars in different regions
  • Current and future trends in global oncology biosimilars market
  • Challenges for new entrants

PART 07: Global pharmaceutical market

  • Market size and forecast
  • Global biosimilars market

PART 08: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 09: Market segmentation by end-user

  • Hospitals
  • Retail pharmacies

PART 10: Market segmentation by application

  • Cancer treatment drugs
  • Supportive care drugs

PART 11: Geographical segmentation

  • Global oncology biosimilar drugs market by geographical segmentation 2015-2020
  • Oncology biosimilars market in EMEA
  • Oncology biosimilars market in APAC
  • Oncology biosimilars market in Americas

PART 12: Key leading regions

  • US
  • Europe
  • Japan
  • India
  • China

PART 13: Market drivers

  • Rise in number of patent expiries
  • Increase in prevalence of cancer
  • Growing aging population
  • Promising drug pipeline
  • Need for cost-effective treatment
  • Favorable government regulations

PART 14: Impact of drivers

PART 15: Market challenges

  • Risks related to failure of drugs in market
  • Multiple manufacturing complexities
  • Reluctance among physicians to prescribe biosimilar products
  • Complicated regulatory process
  • Limited availability of biosimilar products
  • Risk of side effects

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Emergence of biosimilars
  • Outsourcing of biosimilar manufacturing activities
  • Rising number of strategic collaborations
  • Increase in cancer awareness
  • Rise in R&D

PART 18: Vendor landscape

  • Competitive scenario
  • Biocon
  • Celltrion
  • Dr. Reddy's Laboratories
  • F Hoffmann-La Roche
  • Hospira
  • Mylan
  • Sandoz
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global biosimilars and oncology biosimilars market 2015
  • Exhibit 03: Cancer burden in European Union (EU)
  • Exhibit 04: Global incidence of cancer 2015
  • Exhibit 05: Global mortality of cancer type 2015
  • Exhibit 06: Estimated numbers of cancer survivors by age in US 2014
  • Exhibit 07: Definition of biosimilars in different regions
  • Exhibit 08: Comparison between biosimilars and generic small molecules
  • Exhibit 09: Factors influencing biologics and biosimilars
  • Exhibit 10: Impact of biosimilars cost savings on various sectors
  • Exhibit 11: Factors affecting success of biosimilars
  • Exhibit 12: Biosimilars industry: Point-of-view
  • Exhibit 13: Factors affecting the uptake of biosimilars
  • Exhibit 14: Strategic factors for new entrant
  • Exhibit 15: Growth of biosimilars
  • Exhibit 16: Share of biosimilars in recombinant drugs sales in major markets 2014
  • Exhibit 17: Trends in global oncology biosimilars market
  • Exhibit 18: Challenges for new entrants
  • Exhibit 19: Global pharmaceutical market 2015-2020 ($ trillions)
  • Exhibit 20: Global biosimilars market 2015-2020 ($ billions)
  • Exhibit 21: Number of approved biosimilars in regulated and semi-regulated markets
  • Exhibit 22: Global pharmaceutical, biosimilars, and oncology biosimilars market 2015 ($ billions)
  • Exhibit 23: Global oncology biosimilars market 2015-2020 ($ billions)
  • Exhibit 24: Global oncology biosimilars market overview
  • Exhibit 25: Five forces analysis
  • Exhibit 26: Oncology biosimilars market segmentation by end-user 2014
  • Exhibit 27: Global oncology biosimilars segmentation by application
  • Exhibit 28: Oncology biosimilars by application
  • Exhibit 29: Global oncology biosimilars market by geographical segmentation 2015
  • Exhibit 30: Global oncology biosimilars market revenue by geography 2015-2020 ($ billions)
  • Exhibit 31: Oncology biosimilars market in EMEA 2015-2020 ($ billions)
  • Exhibit 32: Oncology biosimilars market in APAC 2015-2020 ($ billions)
  • Exhibit 33: Oncology biosimilars market in Americas 2015-2020 ($ billions)
  • Exhibit 34: Global oncology biosimilars market: YoY revenue and growth based on geography 2015-2020 ($ billions)
  • Exhibit 35: Key leading regions
  • Exhibit 36: Pharmaceutical R&D expenditure in US 2010-2015 ($ billions)
  • Exhibit 37: Approvals of biologicals versus biosimilars via PHSA
  • Exhibit 38: Approval process for biosimilars in US
  • Exhibit 39: Benefits of biosimilars to US healthcare system
  • Exhibit 40: Role of stake holders
  • Exhibit 41: SWOT analysis
  • Exhibit 42: Oncology biosimilars approved by EMA in Europe
  • Exhibit 43: Guidelines for biosimilars in EU
  • Exhibit 44: Time line of biosimilars in Europe
  • Exhibit 45: Key stake holders
  • Exhibit 46: Key drivers and restraints
  • Exhibit 47: Biosimilar industry challenges in Europe
  • Exhibit 48: SWOT analysis
  • Exhibit 49: Biosimilars approved by PMDA in Japan
  • Exhibit 50: Review process for biosimilars in Japan
  • Exhibit 51: Drivers and challenges in oncology biosimilars market in Japan
  • Exhibit 52: SWOT analysis
  • Exhibit 53: Biosimilars approved in India
  • Exhibit 54: Timeline for development of biosimilars in India
  • Exhibit 55: Challenges and strategies
  • Exhibit 56: Major domestic and international vendors operating in India
  • Exhibit 57: Drivers and challenges
  • Exhibit 58: SWOT analysis
  • Exhibit 59: Top domestic and international vendors operating in China
  • Exhibit 60: Drivers and challenges
  • Exhibit 61: SWOT analysis
  • Exhibit 62: Patent expiries of oncology biologics in US and EU 2020
  • Exhibit 63: Global incidence of cancer 2015 and 2020
  • Exhibit 64: Impact of drivers
  • Exhibit 65: Impact of drivers and challenges
  • Exhibit 66: Global competitive landscape 2015
  • Exhibit 67: Biocon: Key takeaways
  • Exhibit 68: Celltrion: Key takeaways
  • Exhibit 69: Dr. Reddy's Laboratories: Key takeaways
  • Exhibit 70: F. Hoffmann-La: Key takeaways
  • Exhibit 71: Hospira: Key takeaways
  • Exhibit 72: Mylan: Key takeaways
  • Exhibit 73: Sandoz: Key takeaways
Back to Top